Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tina Moser

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
International Journal of Cancer|September 19, 2020
A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot studyMatthias Unseld, Jelena Belic, Kerstin Pierer, et al.
Therapeutic Advances in Medical Oncology|August 9, 2021
Molecular profiling of soft-tissue sarcomas with FoundationOne<sup>®</sup> Heme identifies potential targets for sarcoma therapy: a single-centre experienceSusanne Scheipl, Iva Brcic, Tina Moser, et al.
British Journal of Cancer|January 9, 2026
Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibilityGeorgios Vlachos, Tina Moser, Isaac Lazzeri, et al.
Clinical Chemistry|July 3, 2024
Clinical Application of ISO and CEN/TS Standards for Liquid Biopsies-Information Everybody Wants but Nobody Wants to Pay ForLilli Bonstingl, Christina Skofler, Christine Ulz, et al.
Iscience|October 27, 2025
Evaluation of urinary cfDNA workflows for the molecular profiling of malignant diseaseAnna Eberhard, Tina Moser, Leandra Ziegler, et al.
NPJ Precision Oncology|December 10, 2020
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancerTina Moser, Julie Waldispuehl-Geigl, Jelena Belic, et al.
JCO Precision Oncology|January 7, 2022
Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint InhibitorsSabrina Weber, Paul van der Leest, Hylke C Donker, et al.
Nature Communications|April 22, 2020
Publisher Correction: Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detectionPeter Ulz, Samantha Perakis, Qing Zhou, et al.
Nature Communications|October 13, 2019
Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detectionPeter Ulz, Samantha Perakis, Qing Zhou, et al.
Genome Medicine|March 1, 2020
Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumorsChristopher G Smith, Tina Moser, Florent Mouliere, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
International Journal of Cancer|September 19, 2020
A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot studyMatthias Unseld, Jelena Belic, Kerstin Pierer, et al.
Therapeutic Advances in Medical Oncology|August 9, 2021
Molecular profiling of soft-tissue sarcomas with FoundationOne<sup>®</sup> Heme identifies potential targets for sarcoma therapy: a single-centre experienceSusanne Scheipl, Iva Brcic, Tina Moser, et al.
British Journal of Cancer|January 9, 2026
Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibilityGeorgios Vlachos, Tina Moser, Isaac Lazzeri, et al.
Clinical Chemistry|July 3, 2024
Clinical Application of ISO and CEN/TS Standards for Liquid Biopsies-Information Everybody Wants but Nobody Wants to Pay ForLilli Bonstingl, Christina Skofler, Christine Ulz, et al.
Iscience|October 27, 2025
Evaluation of urinary cfDNA workflows for the molecular profiling of malignant diseaseAnna Eberhard, Tina Moser, Leandra Ziegler, et al.
NPJ Precision Oncology|December 10, 2020
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancerTina Moser, Julie Waldispuehl-Geigl, Jelena Belic, et al.
JCO Precision Oncology|January 7, 2022
Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint InhibitorsSabrina Weber, Paul van der Leest, Hylke C Donker, et al.
Nature Communications|April 22, 2020
Publisher Correction: Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detectionPeter Ulz, Samantha Perakis, Qing Zhou, et al.
Nature Communications|October 13, 2019
Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detectionPeter Ulz, Samantha Perakis, Qing Zhou, et al.
Genome Medicine|March 1, 2020
Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumorsChristopher G Smith, Tina Moser, Florent Mouliere, et al.
Pageof 2